Table 2

Baseline Characteristics

All TherapiesSunitinibSorafenibPazopanibBevacizumabEverolimusTemsirolimus
Patients (n)1591017343312417
Age (yrs)60.859.262.962.761.060.558.4
Men122 (77%)78 (77%)60 (82%)34 (79%)24 (77%)20 (83%)16 (94%)
Women37 (23%)23 (23%)13 (18%)9 (21%)7 (23%)4 (17%)1 (6%)
ECOG performance status1111111
Heart Failure5 (3%)2 (2%)3 (4%)1 (2%)0 (0%)1 (4%)0 (0%)
Hypertension74 (47%)44 (44%)38 (52%)21 (49%)16 (52%)12 (50%)6 (35%)
Coronary artery disease10 (6%)9 (9%)4 (5%)1 (2%)1 (3%)2 (8%)0 (0%)
Diabetes mellitus19 (12%)14 (14%)10 (14%)7 (16%)3 (10%)2 (8%)2 (12%)
Hyperlipidemia38 (24%)25 (25%)19 (26%)16 (37%)6 (19%)10 (42%)2 (12%)
Atrial fibrillation6 (4%)1 (1%)3 (4%)2 (5%)3 (10%)1 (4%)1 (6%)
Previous stroke or TIA3 (2%)1 (1%)2 (3%)0 (0%)0 (0%)1 (4%)1 (6%)
Additional malignancy5 (3%)4 (4%)1 (1%)2 (5%)0 (0%)0 (0%)0 (0%)

Note: patients who received multiple therapies in succession are counted only once in “All Therapies.”

ECOG = Eastern Cooperative Oncology Group; TIA = transient ischemic attack.